CARY, NC--(Marketwired - Jun 13, 2013) - Cornerstone Therapeutics Inc. (
Cornerstone is currently reviewing the details of this Notice Letter and will pursue all available legal and regulatory avenues in defense of CARDENE® I.V. (nicardipine hydrochloride) Premixed Injection, including enforcement of their intellectual property rights and approved labeling.
About Cornerstone Therapeutics
Cornerstone Therapeutics Inc. (
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to satisfy FDA and other regulatory requirements, our ability to develop and maintain the necessary sales, marketing, supply chain and distribution capabilities to successfully commercialize our products, our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 14, 2013 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs only as of the date of this release. We anticipate that subsequent events and developments may cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as may be required by law. Our forward-looking statements do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.
Trademarks
CARDENE® I.V. is a registered trademark of EKR Therapeutics, Inc., Cornerstone Therapeutics' wholly-owned subsidiary.
Contact Information:
Contacts
Investor Relations Contact:
Josh Franklin
Vice President, Strategy and Business Development
+1-919-678-6520
josh.franklin@crtx.com
Media Relations Contact:
Fleishman-Hillard
Andrea Moody
+1-919-457-0743
andrea.moody@fleishman.com